BP
NVS icon

Ballentine Partners’s Novartis NVS Stock Holding History

Ballentine Partners’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Buy
29,508
+1,429
+5% +$214K 0.06% 115
2026
Q1 		$4.29M Buy
28,079
+1,098
+4% +$168K 0.06% 108
2025
Q4 		$3.72M Buy
26,981
+862
+3% +$113K 0.05% 120
2025
Q3 		$3.35M Sell
26,119
-632
-2% -$77.1K 0.05% 129
2025
Q2 		$3.24M Buy
26,751
+1,126
+4% +$127K 0.05% 131
2025
Q1 		$2.86M Buy
25,625
+6,391
+33% +$680K 0.05% 133
2024
Q4 		$1.87M Buy
19,234
+824
+4% +$87.9K 0.03% 183
2024
Q3 		$2.12M Buy
18,410
+1,030
+6% +$117K 0.04% 164
2024
Q2 		$1.85M Buy
17,380
+2,000
+13% +$201K 0.03% 168
2024
Q1 		$1.49M Buy
15,380
+1,788
+13% +$183K 0.03% 188
2023
Q4 		$1.37M Buy
13,592
+2,339
+21% +$226K 0.03% 191
2023
Q3 		$1.15M Buy
11,253
+783
+7% +$79.5K 0.03% 185
2023
Q2 		$1.06M Buy
10,470
+2,403
+30% +$240K 0.02% 194
2023
Q1 		$742K Buy
8,067
+160
+2% +$14K 0.02% 234
2022
Q4 		$717K Sell
7,907
-1,785
-18% -$150K 0.02% 223
2022
Q3 		$736K Buy
9,692
+38
+0.4% +$3.15K 0.03% 190
2022
Q2 		$816K Sell
9,654
-2,651
-22% -$233K 0.03% 176
2022
Q1 		$1.08M Buy
12,305
+3,661
+42% +$317K 0.03% 164
2021
Q4 		$756K Buy
8,644
+20
+0.2% +$1.66K 0.02% 212
2021
Q3 		$705K Buy
8,624
+518
+6% +$46.6K 0.02% 193
2021
Q2 		$740K Sell
8,106
-10
-0.1% -$890 0.03% 180
2021
Q1 		$693K Sell
8,116
-490
-6% -$44K 0.03% 183
2020
Q4 		$813K Buy
8,606
+194
+2% +$17K 0.03% 160
2020
Q3 		$732K Buy
8,412
+388
+5% +$33.6K 0.03% 166
2020
Q2 		$700K Sell
8,024
-293
-4% -$25.3K 0.03% 173
2020
Q1 		$685K Sell
8,317
-521
-6% -$46.5K 0.04% 155
2019
Q4 		$837K Buy
8,838
+447
+5% +$40.1K 0.04% 174
2019
Q3 		$730K Buy
8,391
+63
+0.8% +$5.66K 0.03% 177
2019
Q2 		$761K Sell
8,328
-565
-6% -$47.8K 0.04% 175
2019
Q1 		$767K Buy
8,893
+379
+4% +$30.4K 0.04% 155
2018
Q4 		$655K Buy
8,514
+760
+10% +$59.2K 0.04% 164
2018
Q3 		$598K Buy
7,754
+133
+2% +$9.83K 0.03% 176
2018
Q2 		$516K Buy
7,621
+9
+0.1% +$621 0.03% 180
2018
Q1 		$552K Buy
7,612
+164
+2% +$12.5K 0.03% 169
2017
Q4 		$561K Buy
7,448
+211
+3% +$15.9K 0.03% 173
2017
Q3 		$557K Sell
7,237
-271
-4% -$20.5K 0.03% 180
2017
Q2 		$563K Buy
7,508
+1,959
+35% +$139K 0.04% 183
2017
Q1 		$370K Sell
5,549
-626
-10% -$41.7K 0.03% 154
2016
Q4 		$403K Buy
6,175
+636
+11% +$41.3K 0.03% 129
2016
Q3 		$392K Sell
5,539
-103
-2% -$7.51K 0.03% 119
2016
Q2 		$417K Buy
5,642
+643
+13% +$44.4K 0.04% 125
2016
Q1 		$324K Sell
4,999
-151
-3% -$10.3K 0.03% 149
2015
Q4 		$398K Buy
5,150
+297
+6% +$23.6K 0.04% 113
2015
Q3 		$400K Buy
4,853
+524
+12% +$46.6K 0.04% 105
2015
Q2 		$382K Hold
4,329
– – 0.04% 111
2015
Q1 		$383K Sell
4,329
-12,254
-74% -$1.09M 0.04% 110
2014
Q4 		$1.38M Buy
16,583
+12,254
+283% +$1.02M 0.16% 38
2014
Q3 		$365K Hold
4,329
– – 0.04% 105
2014
Q2 		$351K Hold
4,329
– – 0.04% 102
2014
Q1 		$329K Buy
4,329
+256
+6% +$18.7K 0.04% 106
2013
Q4 		$293K Hold
4,073
– – 0.03% 117
2013
Q3 		$280K Hold
4,073
– – 0.03% 116
2013
Q2 		$258K Buy
+4,073
New +$265K 0.03% 107

Other funds holding NVS

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
SI
Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
MIM
Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MGIA
Matthew Goff Investment Advisor Houston, Texas $593M AUM 28.9% 1-Year Est. Return
ERP
Eldred Rock Partners San Antonio, Texas $465M AUM 48.86% 1-Year Est. Return
CCM
Cohen Capital Management Corte Madera, California $735M AUM 36.88% 1-Year Est. Return

Ballentine Partners's NVS Position: Q2 2026 in Review

Ballentine Partners increased its Novartis (NVS) stake by 5.1% in Q2 2026, buying an estimated $214K and bringing the position to 29,508 shares worth $4.62M. The position accounts for 0.06% of the portfolio, ranked #115.

Ballentine Partners first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. 285 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Ballentine Partners held 29,508 shares of Novartis worth $4.62M as of Q2 2026.
  • Ballentine Partners bought 1,429 Novartis shares in Q2 2026, an estimated $214K.
  • Novartis made up 0.06% of Ballentine Partners's portfolio in Q2 2026, its #115 holding.
  • Ballentine Partners first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • 285 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.